"Citi's thesis rests on the 'humanization' of pets. The firm says the humanization pet trend is real and should drive more spending, a view supported by data showing nearly 40% of dogs of any age or size may be affected by OA pain and up to 40% of all cats have clinical signs of OA."
"Zoetis is the world's largest producer of medicine and vaccinations for pets and livestock, with FY2025 revenue of $9.467 billion and a market cap of roughly $51 billion."
"Citi also opened an 'upside 90-day catalyst watch' on Zoetis, saying Solensia will return to growth in fiscal 2026. That's a specific near-term signal worth watching, especially since U.S. mAb products including Librela and Solensia declined in Q4 2025."
Citi has initiated coverage of Zoetis with a Buy rating and a $145 price target, highlighting it as a top pick in the animal health sector. The firm emphasizes the trend of pet humanization, which is expected to increase spending on pet care. Zoetis, as the largest producer of animal medicine, reported significant revenue and is poised for growth with new product launches. The company has received regulatory approvals for long-acting pain management products, further strengthening its market position.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]